IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Amarin Reports 2026 First Quarter Financial Results
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Amarin Q4 Earnings Call Highlights
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
New Strong Sell Stocks for January 28th
US Supreme Court to hear 'skinny label' patent fight involving Amarin
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Amarin (NASDAQ:AMRN) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
Amarin Corporation PLC $AMRN Stock Holdings Decreased by Acadian Asset Management LLC
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?
Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript
Amarin Reports Second Quarter 2025 Financial Results
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
3 Strong Buy Breakout Stocks for Explosive Returns
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Best Momentum Stock to Buy for June 27th
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy?
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Best Momentum Stocks to Buy for June 10th
New Strong Buy Stocks for June 10th